Why the study?
Does androgen deprivation therapy increase the risk of cardiovascular events in men newly diagnosed with prostate cancer?
Population
20,216 men newly diagnosed with prostate cancer between 2009 and 2015 in Scotland.
Comparison
Androgen deprivation therapy including GnRH… vs Untreated patients.
Design
Cohort
Follow-up
73,570 person-years total
Key result
Androgen deprivation therapy was associated with a 25% increase in cardiovascular events (HR 1.25) compared with untreated patients, reflecting increases with GnRH agonists and degarelix.
Authors
Loading...
May warrant CV surveillance with ADT in prostate cancer; extends observational data but leaves causality open for RCTs.
Cohort (n=20,216)
Yes
Does androgen deprivation therapy increase the risk of cardiovascular events in men newly diagnosed with prostate cancer?
Effect estimate: HR 1.25 (95% CI 1.16-1.35)
In a real-world cohort of prostate cancer patients, androgen deprivation therapy with GnRH agonists or degarelix was associated with a significantly increased risk of cardiovascular events, whereas bicalutamide monotherapy was not.
Cardwell et al. (2019) conducted a cohort in Prostate cancer (n=20,216). Androgen deprivation therapy (ADT) vs. Untreated patients (active surveillance or watchful waiting) was evaluated on Cardiovascular event (death from cardiovascular disease or hospitalisation for cardiovascular disease) (HR 1.25, 95% CI 1.16-1.35). Androgen deprivation therapy was associated with a 25% increase in cardiovascular events (HR 1.25) compared with untreated patients, reflecting increases with GnRH agonists and degarelix.